Bongoni Anjan K, Kiermeir David, Jenni Hansjörg, Bähr Andrea, Ayares David, Klymiuk Nikolai, Wolf Eckhard, Voegelin Esther, Constantinescu Mihai A, Seebach Jörg D, Rieben Robert
Department of Clinical Research, University of Bern, Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland; Clinic of Plastic and Hand Surgery, University Hospital, Bern, Switzerland.
Xenotransplantation. 2014 May-Jun;21(3):230-43. doi: 10.1111/xen.12090. Epub 2014 Mar 17.
Besides α1,3-galactosyltransferase gene (GGTA1) knockout, several transgene combinations to prevent pig-to-human xenograft rejection are currently being investigated. In this study, the potential of combined overexpression of human CD46 and HLA-E to prevent complement- and NK-cell-mediated xenograft rejection was tested in an ex vivo pig-to-human xenoperfusion model.
α1,3-Galactosyltransferase knockout heterozygous, hCD46/HLA-E double transgenic (transgenic) as well as wild-type pig forelimbs were ex vivo perfused with whole, heparinized human and autologous pig blood, respectively. Blood samples were analyzed for the production of porcine and/or human inflammatory cytokines as well as complement activation products. Biopsy samples were examined for deposition of human and porcine C3b/c, C4b/c, and C6 as well as CD62E (E-selectin) and CD106 (VCAM-1) expression. Apoptosis was measured in the porcine muscle tissue using TUNEL assays. Finally, the formation of thrombin-antithrombin (TAT) complexes was measured in EDTA plasma samples.
No hyperacute rejection was seen in this model. Extremity perfusions lasted for up to 12 h without increase in vascular resistance and were terminated due to continuous small blood losses. Plasma levels of porcine cytokines IL1β, IL-6, IL-8, IL-10, TNF-α, and MCP-1 as well as human complement activation markers C3a (P = 0.0002), C5a (P = 0.004), and soluble C5b-9 (P = 0.03) were lower in blood perfused through transgenic as compared to wild-type limbs. Human C3b/c, C4b/c, and C6 as well as CD62E and CD106 were deposited in tissue of wild-type limbs, but significantly lower levels (P < 0.0001) of C3b/c, C4b/c, and C6 deposition as well as CD62E and CD106 expression were detected in transgenic limbs perfused with human blood. Transgenic porcine tissue was protected from xenoperfusion-induced apoptosis (P < 0.0001). Finally, TAT levels were significantly lower (P < 0.0001) in transgenic limb as compared to wild-type limb xenoperfusions.
Transgenic hCD46/HLA-E expression clearly reduced humoral xenoresponses since all, the terminal pathway of complement activation, endothelial cell activation, muscle cell apoptosis, inflammatory cytokine production, as well as coagulation activation, were all downregulated. Overall, this model represents a useful tool to study early immunological responses during pig-to-human vascularized xenotransplantation in the absence of hyperacute rejection.
除α1,3-半乳糖基转移酶基因(GGTA1)敲除外,目前正在研究几种转基因组合以防止猪到人的异种移植排斥反应。在本研究中,在体外猪到人的异种灌注模型中测试了人CD46和HLA-E联合过表达预防补体和自然杀伤细胞介导的异种移植排斥反应的潜力。
分别用全血、肝素化的人血和自体猪血对α1,3-半乳糖基转移酶敲除杂合子、hCD46/HLA-E双转基因(转基因)以及野生型猪的前肢进行体外灌注。分析血样中猪和/或人炎症细胞因子的产生以及补体激活产物。检查活检样本中人及猪C3b/c、C4b/c和C6的沉积以及CD62E(E-选择素)和CD106(血管细胞黏附分子-1)的表达。使用TUNEL检测法测量猪肌肉组织中的细胞凋亡。最后,在EDTA血浆样本中测量凝血酶-抗凝血酶(TAT)复合物的形成。
在该模型中未观察到超急性排斥反应。肢体灌注持续长达12小时,血管阻力没有增加,因持续少量失血而终止。与野生型肢体相比,灌注转基因肢体的血液中猪细胞因子IL1β、IL-6、IL-8、IL-10、TNF-α和MCP-1以及人补体激活标志物C3a(P = 0.0002)、C5a(P = 0.004)和可溶性C5b-9(P = 0.03)的血浆水平较低。人C3b/c、C4b/c和C6以及CD62E和CD106沉积在野生型肢体组织中,但在灌注人血的转基因肢体中检测到的C3b/c、C4b/c和C6沉积水平以及CD62E和CD106表达明显较低(P < 0.0001)。转基因猪组织免受异种灌注诱导的细胞凋亡(P < 0.0001)。最后,与野生型肢体异种灌注相比,转基因肢体中的TAT水平显著降低(P < 0.0001)。
转基因hCD46/HLA-E表达明显降低了体液异种反应,因为补体激活的终末途径、内皮细胞激活、肌肉细胞凋亡、炎症细胞因子产生以及凝血激活均被下调。总体而言,该模型是研究在无超急性排斥反应情况下猪到人的血管化异种移植早期免疫反应的有用工具。